Pfizer, Atavistik to collaborate on allosteric drug discovery

Pfizer (NYSE:PFE) has entered into a collaborative research agreement with Atavistik Bio for the discovery of novel precision allosteric therapeutics.

The collaboration will utilize Atavistik’s AMPS platform to identify novel allosteric binders against two undisclosed targets selected by Pfizer (NYSE:PFE), which will also have an option to license the programs. 

Financial terms of the agreement were not disclosed.